| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Auristatin
Fmoc-MMAE targets tubulin, a key component of the cytoskeleton. As a derivative of MMAE, it inhibits tubulin polymerization, disrupting microtubule dynamics and leading to cell cycle arrest and apoptosis. The compound's mechanism of action is typical of auristatin-class antimitotic agents, which bind to the vinca domain of tubulin and prevent microtubule assembly. |
|---|---|
| ln Vitro |
Fmoc-MMAE demonstrates potent in vitro cytotoxicity against cancer cells, consistent with MMAE's activity as a tubulin inhibitor. The compound's activity is typically evaluated after conjugation to an antibody in the context of ADC research. The Fmoc group protects the amine functionality during synthesis and is removed prior to or during conjugation.
|
| ln Vivo |
In vivo activity of Fmoc-MMAE is observed in the context of ADCs synthesized using this compound. These ADCs demonstrate targeted antitumor efficacy in animal models by delivering the potent MMAE payload specifically to tumor cells. The compound's utility is in enabling the synthesis of ADCs with potent antitumor activity.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Fmoc-MMAE are not typically performed, as it is a protected payload for ADC synthesis. Its activity as a tubulin inhibitor is assessed after deprotection or in the context of the final ADC. Tubulin polymerization assays can be used to confirm the compound's mechanism of action.
|
| Cell Assay |
In vitro cellular assays for Fmoc-MMAE involve evaluating the cytotoxicity of ADCs synthesized using this compound against target cancer cell lines. Cell viability is assessed using MTT or other assays, and IC50 values are determined to evaluate the potency of the ADC. The compound itself is not typically tested directly on cells due to the Fmoc protecting group.
|
| Animal Protocol |
In vivo animal experiments for Fmoc-MMAE involve administering ADCs synthesized with this compound to tumor-bearing mouse models. Efficacy is evaluated by measuring tumor growth inhibition, survival rates, and body weight changes. The compound's role is as a cytotoxic payload component of the ADC.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-MMAE are typically derived from studies of ADCs synthesized using this compound. The payload's release and distribution are influenced by the linker and conjugation strategy. The compound's stability and pharmacokinetic properties are important considerations for ADC development.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fmoc-MMAE are typically derived from studies of ADCs synthesized using this compound. The compound is a potent cytotoxic agent and should be handled with appropriate safety precautions. It is intended for research use only and is not for human therapeutic application.
|
| References | |
| Additional Infomation |
Fmoc-MMAE (CAS#: 474645-26-6) has the molecular formula C54H77N5O9 and a molecular weight of 940.22 g/mol. Its purity is ≥98%. The compound is used in ADC research as a cytotoxic payload and is for research use only.
|
| Molecular Formula |
C54H77N5O9
|
|---|---|
| Molecular Weight |
940.22
|
| Exact Mass |
939.572
|
| CAS # |
474645-26-6
|
| PubChem CID |
78358314
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
1036.4±65.0 °C at 760 mmHg
|
| Flash Point |
580.6±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.556
|
| LogP |
8.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
68
|
| Complexity |
1620
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3C4=CC=CC=C4C5=CC=CC=C35
|
| InChi Key |
ZBRLIYBOHHIZKY-NMDVRVFRSA-N
|
| InChi Code |
InChI=1S/C54H77N5O9/c1-13-34(6)48(44(66-11)30-45(60)59-29-21-28-43(59)50(67-12)35(7)51(62)55-36(8)49(61)37-22-15-14-16-23-37)57(9)53(64)46(32(2)3)56-52(63)47(33(4)5)58(10)54(65)68-31-42-40-26-19-17-24-38(40)39-25-18-20-27-41(39)42/h14-20,22-27,32-36,42-44,46-50,61H,13,21,28-31H2,1-12H3,(H,55,62)(H,56,63)/t34-,35+,36+,43-,44+,46-,47-,48-,49+,50+/m0/s1
|
| Chemical Name |
9H-fluoren-9-ylmethyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 45 mg/mL (47.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0636 mL | 5.3179 mL | 10.6358 mL | |
| 5 mM | 0.2127 mL | 1.0636 mL | 2.1272 mL | |
| 10 mM | 0.1064 mL | 0.5318 mL | 1.0636 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
